BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24386905)

  • 1. Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk.
    Tai LM; Mehra S; Shete V; Estus S; Rebeck GW; Bu G; LaDu MJ
    Mol Neurodegener; 2014 Jan; 9():2. PubMed ID: 24386905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.
    Tai LM; Bilousova T; Jungbauer L; Roeske SK; Youmans KL; Yu C; Poon WW; Cornwell LB; Miller CA; Vinters HV; Van Eldik LJ; Fardo DW; Estus S; Bu G; Gylys KH; Ladu MJ
    J Biol Chem; 2013 Feb; 288(8):5914-26. PubMed ID: 23293020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.
    Youmans KL; Tai LM; Nwabuisi-Heath E; Jungbauer L; Kanekiyo T; Gan M; Kim J; Eimer WA; Estus S; Rebeck GW; Weeber EJ; Bu G; Yu C; Ladu MJ
    J Biol Chem; 2012 Dec; 287(50):41774-86. PubMed ID: 23060451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
    Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
    J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
    Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
    Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.
    Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM
    Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.
    Deane R; Sagare A; Hamm K; Parisi M; Lane S; Finn MB; Holtzman DM; Zlokovic BV
    J Clin Invest; 2008 Dec; 118(12):4002-13. PubMed ID: 19033669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.
    Valencia-Olvera AC; Balu D; Bellur S; McNally T; Saleh Y; Pham D; Ghura S; York J; Johansson JO; LaDu MJ; Tai L
    Alzheimers Res Ther; 2023 Dec; 15(1):216. PubMed ID: 38102668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation.
    Valencia-Olvera AC; Balu D; Faulk N; Amiridis A; Wang Y; Pham C; Avila-Munoz E; York JM; Thatcher GRJ; LaDu MJ
    Neurotherapeutics; 2023 Jul; 20(4):1120-1137. PubMed ID: 37157042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.
    Hashimoto T; Serrano-Pozo A; Hori Y; Adams KW; Takeda S; Banerji AO; Mitani A; Joyner D; Thyssen DH; Bacskai BJ; Frosch MP; Spires-Jones TL; Finn MB; Holtzman DM; Hyman BT
    J Neurosci; 2012 Oct; 32(43):15181-92. PubMed ID: 23100439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.
    Tachibana M; Holm ML; Liu CC; Shinohara M; Aikawa T; Oue H; Yamazaki Y; Martens YA; Murray ME; Sullivan PM; Weyer K; Glerup S; Dickson DW; Bu G; Kanekiyo T
    J Clin Invest; 2019 Mar; 129(3):1272-1277. PubMed ID: 30741718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.
    Liao F; Li A; Xiong M; Bien-Ly N; Jiang H; Zhang Y; Finn MB; Hoyle R; Keyser J; Lefton KB; Robinson GO; Serrano JR; Silverman AP; Guo JL; Getz J; Henne K; Leyns CE; Gallardo G; Ulrich JD; Sullivan PM; Lerner EP; Hudry E; Sweeney ZK; Dennis MS; Hyman BT; Watts RJ; Holtzman DM
    J Clin Invest; 2018 May; 128(5):2144-2155. PubMed ID: 29600961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
    Nakamura T; Kawarabayashi T; Ueda T; Shimomura S; Hoshino M; Itoh K; Ihara K; Nakaji S; Takatama M; Ikeda Y; Shoji M
    J Alzheimers Dis; 2023; 93(1):333-348. PubMed ID: 36970894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
    Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
    FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
    Aleshkov S; Abraham CR; Zannis VI
    Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOE effects on regional tau in preclinical Alzheimer's disease.
    Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
    Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
    Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
    J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of amyloid-beta with ApoE.
    Carter DB
    Subcell Biochem; 2005; 38():255-72. PubMed ID: 15709483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.
    Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R
    J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of amyloid-β in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging.
    Honda K; Saito Y; Saito H; Toyoda M; Abe R; Saito T; Saido TC; Michikawa M; Taru H; Sobu Y; Hata S; Nakaya T; Suzuki T
    Neurobiol Aging; 2023 Mar; 123():63-74. PubMed ID: 36638682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.